Chemotherapy and immunotherapy combinations for the treatment of leukemia

Share This Post

According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab nivolumab ) showed that the response rate and recurrence of patients with relapsed or refractory acute myeloid leukemia ( AML ) The overall survival rate is encouraging.

The study followed 70 patients. After an average of 2 lines of treatment, relapsed AML reported an overall response rate of 33 % and a complete response rate of 22 %. The drug combination is particularly effective for patients who have not previously received hypomethylation agents ( HMA ) such as azacitidine or decitabine, and the total effective rate of these patients is 52 %.

The researchers said that bone marrow samples collected before treatment showed that the frequency of prediction of bone marrow CD3 and CD8 cells before treatment was higher. In particular, CD3 seems to have a high sensitivity and specificity rate to predict the response, indicating that it can be used as a reliable biomarker for selecting patients for this combination therapy. “

Treatment includes intravenous or subcutaneous injection of azacitidine and intravenous injection of nivolumab . Although most patients have been successfully treated, 11 % of patients still have serious or potentially life-threatening side effects. The overall survival of all patients was 6.3 months. The survival rate of patients with first relapse was 10.6 months, which was twice the survival rate observed with azacitidine alone in similar patients in MD Anderson .

Researcher Daver said that the relevant randomized phase III study is ongoing, and we believe that the implementation of clinical and immune biomarkers for selecting patients may result in further improvements in these types of therapies in AML .

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy